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Abstract. The vascular endothelium participates in angio-
genesis, inflammation and the immune response, which are
modulated by vasoactive cytokines such as tumour necrosis
factor-· (TNF·) and transforming growth factor-ß1 (TGFß1).
CD105 is a component of the TGFß receptor complex and is
abundantly expressed in activated/injured endothelium where it
is implicated in multiple cellular processes. Up-regulation of
CD105 in synovial cells of rheumatoid arthritis and psoriatic
lesions implies a possible role in the pathogenesis of such
inflammatory disorders. The pro-inflammatory cytokine, TNF·,
and anti-inflammatory cytokine, TGFß1, regulate multiple
cellular processes such as proliferation, differentiation and
apoptosis. Our hypothesis is that CD105 gene expression in
endothelial cells is regulated by the multifunctional cytokines
TNF· and TGFß1. By using human dermal microvascular
endothelial cells the present study has shown that long-term
treatment with TNF· (0.1-5 ng/ml) elicited a concentration- and
time-dependent significant suppression (over 50% reduction) in
CD105 protein levels. The observations that no significant
alterations in the CD105 mRNA levels or in the CD105
promoter activity were found and that the potent inhibitor of
NFÎB, PDTC, did not affect the TNF· action suggest that
CD105 down-regulation by TNF· is not at the transcriptional
level. In contrast to TNF·, TGFß1 significantly elevated CD105
protein and mRNA expression (<2-fold increase) through
activation of its promoter activity. From these data we conclude
that TNF· and TGFß1 exert opposing effects on CD105
expression in human vascular endothelial cells and that CD105
is enmeshed in the network of signal pathways modulating
multiple cellular functions. 
The vascular endothelium participates in angiogenesis,
inflammation and the immune response. Cytokines such as
tumour necrosis factor-· (TNF·) and transforming growth
factor-ß1 (TGFß1) modulate these processes partially by
acting on their vascular targets such as vascular endothelial
growth factor (VEGF) and its receptor KDR (1), intercellular
adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1) and E-selectin (2-4). CD105
(endoglin) is an important component in the TGFß receptor
complex that is expressed mainly in vascular endothelial cells
(EC) (5,6) and to a lesser extent in macrophages (7),
erythroid precursors (8), syncytiotrophoblast in placenta (9),
pre-B leukaemic (10), haematopoietic (11), mesangial (12)
and vascular smooth muscle cells (13), implying its
multifunctional potential. CD105 binds TGFß1, TGFß3,
activin-A and BMP-7 and modulates TGFß signalling (14-16).
Haploin-sufficiency of CD105 results in hereditary
haemorrhagic telangiectasia (HHT) type I - an autosomal
dominant vascular disorder (17;18). CD105 knock-out mice
develop severe defects in their vasculature and die in utero.
Suppression of CD105 in vitro leads to inhibition of
angiogenesis (19-22). The expression of CD105 in vascular
endothelial cells of tumours is much more intense than in
normal tissues and correlates with tumour metastasis and
poor prognosis (23-28). Overexpression of CD105 has also
been observed in the synovial cells of rheumatoid arthritis
(RA), psoriatic lesions and in the skin vasculature of patients
with systemic scleroderma, suggesting that it may be
important in the pathogenesis of the inflammatory auto-
immune disorders (29,30 and our unpublished data). 
TGFß, a multifunctional cytokine, modulates angiogenesis
and suppresses inflammation and the immune response
(31,32). With regard to its role in tumour development,
published literature is contradictory - TGFß1 either inhibits
or promotes tumour progression depending on the stage of
the disease (31,33). TGFß signalling can be modified by
CD105 on the one hand, while on the other hand CD105 is
up-regulated by TGFß in cultured human monocytes (15).
There appears to be a mutually dependent regulation
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between CD105 and TGFß1 in CD105 expressing cells. To
ascertain whether this is the case in human vascular EC, the
effect of TGFß1 on the expression of CD105 in human
dermal microvascular EC (HDMEC) was examined.       
TNF·, a pro-inflammatory cytokine, is produced upon
stimulation by monocytes, macrophages, T and B lympho-
cytes, neutrophils and mast cells and is involved in multiple
cellular functions including proliferation, differentiation and
apoptosis (34). In vivo TNF· induces extensive disruption of
tumour vasculature followed by haemorrhagic tumour
necrosis (35,36). The anti-vascular action of TNF· is highly
selective as it has no detectable effect on quiescent vessels
(37,38). However, the molecular basis for the selectivity of
TNF·’s action on angiogenic blood vessels has not been fully
elucidated. Recently TNF· has been reported to suppress the
activation of ·vß3 (36). With regard to inflammatory diseases,
TNF· plays a major role in the pathogenesis of RA and
psoriasis (39,40), wherein the concomitant presence of CD105
has been noted. Accordingly, in this study the effect of TNF·
on the expression of CD105 in HDMEC was examined.   
Materials and ªethods 
HDMEC and cell culture. HDMEC (Clonetics, San Diego, CA, USA)
were grown in complete medium comprising MCDB 131, 10 ng/ml
epithelial growth factor, 10% (v/v) foetal calf serum (FCS) (Life
Technologies), 2 mM glutamine plus 100 Ìg/ml penicillin and 100
Ìg/ml streptomycin. Confluent cells were subcultured using 0.05%
(w/v) trypsin and 2 mM EDTA. These cells express high levels of
CD105 and are also positive for pan-endothelial markers, viz CD31
and von Willebrand factor as determined by immunocytochemistry,
flow cytometry and immunoblotting (data not shown). To study the
gene expression of CD105 in response to cytokines, confluent
HDMEC were maintained in complete medium, containing either
TNF· (0.125 - 5 ng/ml) (Sigma) or TGFß1 (0.001 - 10 ng/ml) (R&D
Systems) for up to 24 hours. Control cells at the same confluency were
maintained in complete medium only (lacking TNF· and TGFß1).
The cultures were rinsed twice with pre-warmed PBS to remove any
detached cells prior to  examination of the following parameters. The
possible effect of pyrrolidinedithiocarbamate (PDTC) (Sigma), a
potent NFÎB inhibitor, on the action of TNF· was examined using
serum-free cultures. Fifty ÌM of PDTC were added to the HDMEC in
the presence or absence of TNF· for 24 hours and CD105 expression
was determined by immunoblotting analysis. 
Indirect immunofluorescence and flow cytometric analysis. The cell surface
expression of CD105 protein was quantified by flow cytometry as
described previously (21). Briefly, 105 cells per tube were incubated with
50 Ìl (10 Ìg/ml in PBS) of monoclonal antibody (mab), E9, to CD105 or
pre-immunised mouse serum as negative control antibody (10 Ìg/ml in
PBS) on ice for 1 hour and washed twice with cold PBS. After incubation
with FITC-labelled rabbit anti-mouse F(ab)2 (1:40; DAKO) for 30
minutes on ice, the cells were washed and re-suspended in 0.3 ml of 2%
buffered formalin and analysed on a Becton Dickinson FACScan flow
cytometer. 
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Figure 1. FACS analysis of CD105 expression. HDMEC were cultured in medium containing TNF· or TGFß1 for 24 hours and CD105 expression was
quantified by FACS. (A) TNF· induced a concentration-dependent reduction of CD105 expression with the maximal effects occurred at 5 ng/ml. (B)
HDMEC were treated with 5 ng/ml of TNF· for various times. TNF· did not significantly alter CD105 levels from 1 to 4 hours, but it did so from 12 to 24
hours of treatment. (C) Treatment with TGFß1 led to a concentration-dependent increase in CD105 expression with the maximal effect occurring at 10
ng/ml. (D) HDMEC were cultured in medium containing 10 ng/ml of TGFß1 for designated times. The cells responded to TGFß1 in a typical time-
dependent manner, with treatment for 24 hours eliciting maximal CD105 expression. Data were expressed as mean±s.e.m.. Each bar represents data
collected from six separate experiments (*p<0.05 and **p<0.01 compared with the control as analysed by one-way ANOVA followed by Duncan test).
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Analysis of CD105 protein expression by immunoblotting. CD105 protein
was extracted from HDMEC by solubilising 1á107 cells/ml with
extraction buffer [0.2% (v/v) NP-40 in 0.1 M Tris buffer (pH 7.3), 0.5
mM PMSF, 1 mM pepstatin, 0.1 mM leupeptin, 1 mM EDTA (BDH)].
The cell lysate was microfuged at 8000ág for 10 minutes at 4ÆC and the
supernatant collected for immunoblotting analysis. Cell lysate
corresponding to 50 Ìg of protein was added to an equal volume of
sample buffer [0.1 M Tris-HCl, 4% (w/v) SDS, 0.001% (w/v)
bromophenol blue, 20% (w/v) glycerol (BDH)] and resolved on 4-7.5%
(w/v) sodium dodecyl sulfate (SDS)-polyacrylamide gel. The fractionated
proteins were electrophoretically transferred onto a PVDF membrane
(Millipore) using the Trans-Blot system (Bio-Rad Laboratories). Filters
were blocked with 2% (w/v) BSA in PBS, 0.1% (v/v) Tween 20 for 2
hours at room temperature. To detect CD105 protein, mab E9 to CD105
(1:1000; 0.5 Ìg/ml) in blocking solution was applied and filters were
incubated overnight at 4ÆC. Finally, the blots were incubated with
horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG
(DAKO) (1:2000 in blocking solution) for 2 hours at 4ÆC with shaking.
The CD105 protein was visualised using the enhanced chemilu-
minescence (ECL) system (Amersham). All chemicals unless specified
were obtained from Sigma.
Analysis of CD105 mRNA by Northern blotting. Total RNA was extracted
using guanidinium thiocyanate/phenol/chloroform. Briefly, HDMEC
cultured in 25-cm2 flasks were lysed in situ by the addition of 1 ml
RNAzol B (Biogenesis). The cell lysate was transferred to clean Corex
tubes, to which 0.2 ml of chloroform was added and mixed by inversion.
Following centrifugation at 8000ág for 15 minutes at 4ÆC, the upper
phase was removed to a clean Corex tube, and an equal volume of
isopropanol added to precipitate the RNA. The RNA was recovered by
centrifugation (8000ág) at 4ÆC for 15 minutes and the pellet was washed
in 70% ethanol and air-dried. The samples were resuspended in 50 Ìl
DEPC H2O on ice and the amount of RNA was quantified by measuring
OD260.
For Northern blot analysis, 20 Ìg of total RNA was denatured and
fractionated in 1% (w/v) agarose / 2.8% (v/v) formaldehyde gel and
capillary blotted onto nitrocellulose. The CD105 cDNA probe was
excised with Eco RI from the pcEXV-EndoL plasmid (15) and the 2.3 kb
fragment was labelled with 32P by random prime labelling. The blot was
hybridised with the 32P-labelled cDNA probe complementary to CD105
mRNA at 65ÆC overnight and the extent of probe hybridisation was
revealed by a phosphorimager (Molecular Dynamics), and analysed
using Image Quant software. The blots were then re-hybridised with 32P-
labelled probe for GAPDH for use as a loading control.
Luciferase reporter gene assay. To determine the CD105 promoter activity
following TNF· or TGFß1 treatment, plasmid pXP2 harbouring the 2.8-
kb (-2450/+350) CD105 promoter (41) and a down-stream firefly
luciferase gene was used for transient transfection of HDMEC. Internal
normalisation was performed by co-transfection of the pXP2 plasmid
with CMVßgal, a ß-galactosidase expression vector driven by the
cytomegalovirus (CMV) promoter. Transfection of HDMEC was carried
out using the liposome-mediated gene transfer technique. Briefly, cells
were seeded at 1á105 cells/35-mm dish and the following day were
transfected with 4 Ìl of DMRIE-C (Life Technologies) plus 1Ìg of
plasmid CMVßgal mixed with 2 Ìg of pXP2 in serum-free medium.
Twenty-four hours after transfection, the cultures were replenished with
complete medium with or without TNF· or TGFß1 and incubated for 24
hours. Thereafter the cells were harvested and the enzyme activity
determined. Luciferase and ß-galactosidase activities were measured on
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Figure 2. Immunoblotting analysis of CD105 expression. CD105 was
extracted from the same batch of cells used for FACS analysis. Fifty Ìg
of total protein was resolved on a 4-7.5% SDS-PAGE under non-
reducing conditions, blotted onto PVDF membrane and probed using
mab E9. (A) It is evident that CD105 levels were diminished by TNF·
treatment. Five ng/ml of TNF· led to greater than 70% reduction of
CD105 protein. (B) CD105 levels were elevated with the increasing
concentration of TGFß1. Ten ng/ml of TGFß1 induced the highest
expression of CD105 protein. (C) The NFÎB inhibitor, PDTC, failed to
reverse the inhibitory effect of TNF· on CD105 expression, suggesting
that the effect of TNF· was not mediated via the NFÎB pathway. Bar-
charts indicate the signal intensity pooled from three experiments as
quantified on a densitometer and expressed as mean±SD. The signal
intensity between TNF· alone and TNF· plus PDTC treated cells was
not significantly different (p>0.05, one-way ANOVA) (*p<0.05 and
**p<0.01 compared with control, one-way ANOVA followed by
Duncan test).
C
a TD-20/20 Luminometer (Promega, UK) and a colorimetric plate
reader (Labsystems) respectively using kits from Promega.
Results
TNF· suppressed but TGFß1 increased expression of CD105
as determined by FACS. HDMEC were grown in medium
containing TNF· (0, 0.125, 0.25, 0.5, 2.5 and 5 ng/ml) or
TGFß1 (0, 0.001, 0.01, 0.1, 1 and 10 ng/ml) for 24 hours.
Cells were harvested and stained with mab E9 to quantify
the cell surface expression of CD105 by FACS. TNF·
suppressed CD105 expression in a concentration-dependent
manner. Five ng/ml of TNF· resulted in a maximal
reduction in CD105 protein levels (approximately 50%)
(Figure 1A). Therefore in subsequent experiments,
HDMEC were treated with this concentration of TNF· (5
ng/ml) for various time courses. A typical time-dependent
response was noted, with maximal suppression occurring at
24 hours, but with significant effects taking place after 12
hours (Figure 1B). 
The addition of TGFß1 resulted in an increased expression
of CD105 - the highest expression (approximately 100%
increase) was elicited by 10 ng/ml (Figure 1C). To examine
whether cellular responses to TGFß1 are time-dependent,
cells were grown in medium supplemented with 10 ng/ml of
TGFß1 for various times. Longer incubation resulted in
higher CD105 expression, demonstrating that TGFß1 up-
regulated CD105 expression in a time-dependent manner
(Figure 1D). 
Immunoblotting analysis of CD105 expression. HDMEC were
treated with various concentrations of TNF· and TGFß1
separately for 24 hours and cell lysate corresponding to 50 Ìg
protein was subjected to SDS-PAGE under non-reducing
conditions, blotted onto PVDF membrane and probed using
mab E9. In all cases one major band of 180 kDa
corresponding to the dimeric form of CD105 was seen on the
blot. As shown in Figure 2A, CD105 levels correlated
inversely with TNF· concentration - for instance, 5 Ìg/ml of
TNF· reduced CD105 levels by approximately 70%. In
contrast, TGFß1 elevated CD105 expression in a
concentration-dependent manner. Ten ng/ml of TGFß1
induced the maximal CD105 expression in comparison with
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Figure 3. Northern blotting analysis of CD105 mRNA expression.  Twenty
micrograms of total RNA were fractionated on a 1% denaturing agarose gel
and transferred onto a nylon membrane. CD105 and GAPDH were probed
using 32P-labelled corresponding cDNAs and visualised on a
Phosphorimager. (A) Treatment with TNF· resulted in an insignificant
alteration of CD105 mRNA (p>0.05, one-way ANOVA). (B) Treatment
with TGFß1 elevated CD105 mRNA in a typical concentration-dependent
manner. In agreement with FACS and immunoblotting analysis, 10 ng/ml of
TGFß1 elicited the strongest signal for CD105 mRNA. Bar charts indicate
the signal intensity pooled from three experiments and expressed as
mean±SD. (*p<0.05, one-way ANOVA followed by Duncan test).
A
B
Figure 4. CD105 promoter activity upon treatment with TGFß1. HDMEC
were co-transfected with plasmids pXP2/pCD105/lux and CMVßgal and
cultured in the presence or absence of TGFß1. Luciferase and ß-
galactosidase activities were determined 24 hours post-treatment. To
eliminate possible variations in cell number and transfection efficiency,
luciferase was normalised to ß-galactosidase activity. TGFß1 treatment
significantly elevated the CD105 promoter activity, which was most evident
at 1 and 10 ng/ml. Data represent six samples at each concentration and
expressed as mean±s.e.m., collected from three separate experiments
(*p<0.05 compared with control medium, one-way ANOVA followed by
Duncan test).    
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the control medium (Figure 2B). To investigate whether
inhibition of the NFÎB affected TNF· regulation on CD105
expression, cells grown in serum-free medium were treated
with 50 ÌM PDTC for 24 hours in the presence or absence of
TNF·. As shown in Figure 2C, TNF· but not PDTC
markedly reduced CD105 levels. The addition of PDTC to
TNF· did not alter the effect of the latter, demonstrating that
the TNF· regulation was not mediated by the NFÎB pathway.
It is also evident that cells cultured in serum-free medium
expressed considerably lower levels of CD105 than those in
medium supplemented with 10% FCS, which is in line with
the data obtained by  FACS (data not shown).
Northern blot of CD105 mRNA from cells following treatment
with TNF· or TGFß1. Total RNA extracted from TNF· or
TGFß1-treated or untreated control cells was fractionated in
a denaturing agarose gel, blotted onto nitrocellulose
membrane and probed using cDNAs to CD105 and GAPDH.
Treatment with TNF· resulted in a negligible reduction of
CD105 mRNA in comparison to GAPDH mRNA, suggesting
that the suppression of CD105 expression by TNF· is not at
the transcriptional level (Figure 3A). The following result
from luciferase reporter gene assay was in favour of this
observation. As shown in Figure 3B, TGFß1 induced a typical
concentration-dependent increase in CD105 mRNA
expression. The expression patterns of mRNA in TGFß1-
treated cells were consistent with the protein levels revealed
by FACS and immunoblotting.  
TGFß1 but not TNF· markedly altered CD105 promoter
activity. To examine whether TNF· and TGFß1 exert their
effects on the CD105 promoter, HDMEC were transiently
transfected with the plasmid pXP2 harbouring a CD105
promoter and a down-stream firefly luciferase gene.
Treatment with TNF· resulted in a negligible suppression of
CD105 promoter activity (data not shown), which was
considered not strong enough to support the transcriptional
regulation. In contrast, upon treatment with TGFß1, CD105
promoter activity was elevated (over 1.5-fold compared with
the basal level), demonstrating that TGFß1 up-regulates
CD105 expression through enhancing its promoter activity
(Figure 4).
Discussion
TNF· and TGFß1 are involved in a number of patho-
physiological settings including angiogenesis, tumour
development, inflammation and immune response. CD105
plays a critical role in maintaining the normal structure and
physiological function of blood vessels and promoting
formation of the neovasculature. The data presented in this
study have revealed an association between CD105 and the
multifuntional proinflammatory cytokine, TNF·, and the
anti-inflammatory cytokine, TGFß1. The implication of these
findings is that CD105 is one of the vascular targets for the
two cytokines and modulates their actions on the vascular
system.
The differential regulation of CD105 by TNF· and TGFß1
in EC is another example of the two cytokines  displaying
contradictory functions. For instance, TNF· and TGFß1
exhibit opposing effects on the expression of cell cycle
proteins such as p21, p27 and cyclin D1 (42), connective tissue
growth factor (43), and matrix metalloproteinase 9 in
monocytes (44). VCAM-1 is one of the indicators of
endothelial damage/activation (2;4). TNF· stimulates the
expression of VCAM-1 but this response is repressed by
TGFß1 in glomerular EC, again indicating the distinct
opposing actions of these two cytokines (45).     
TGFß1 is generally regarded as playing a dual role in
tumour development, i.e. it reduces tumourigenicity of  breast
and lung cancers by suppressing tumour growth and
angiogenesis (46,47) but may promote progression of an
advanced tumour through immune suppression and indirect
stimulation of angiogenesis (33). A number of investigators
have reported that over-expression of TGFß1 in tumour
tissues and in the circulation of patients with late stage
cancers of prostate, stomach, colorectum and lung is
associated with the occurrence of  metastases and shorter
survival (48-50). VEGF has been reported to mediate the
positive effects of TGFß1 in tumour angiogenesis (51). The
present study indicates that CD105 may be another mediator
of the action of TGFß1 on angiogenesis in advanced tumours.
CD105 is over-expressed in tumour tissues and in the
circulation of patients with various types of cancer, Its
expression levels correlate with angiogenesis, metastasis and
poor prognosis (24-26,52,53). Data presented in this study
demonstrate that TGFß1 up-regulates CD105 expression in
vascular EC. The latter, in turn, may promote angiogenesis.
Therefore we speculate that the stimulatory action of TGFß1
on CD105 gene expression contributes to the worsening
prognosis of certain types of advanced cancers. Further
studies are needed to clarify the possible inter-relationship
between TGFß1, CD105, angiogenesis and tumour
progression in the same cohort of patients.        
TNF· has been used for anti-cancer therapy, its target
being the vascular endothelium of the vasculature and not the
tumour cells. Administration of TNF· in patients with
metastatic melanoma resulted in detachment and apoptosis of
EC (35). The inactivation of integrin ·vß3 by TNF· is one of
the contributing factors, but other mechanisms may be
involved in the anti-angiogenic action of TNF· (36). In view
of the putative pro-angiogenic role of CD105, the observed
inhibition of CD105 in EC by TNF· may be another
important contribution to its suppressive effect on tumour
angiogenesis.
Both TNF· and TGFß1 are present in atherosclerotic
lesions and are thought to have key roles in atherogenesis
(54,55). Clinical and experimental evidence suggest that
development of atherosclerotic lesions, which is initiated by
lipoprotein retention and aggregation within the vessel wall,
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can be accelerated by the local action of inflammatory
cytokines such as TNF· on EC. TNF· stimulates expression
of EC genes like VCAM-1 and E-selectin that may exacerbate
the progression of atherosclerosis (45,55). In contrast, TGFß1
is considered to exert atheroprotective effects through
inhibition of smooth muscle cell migration and suppression of
inflammation (56,57). CD105 is present in atherosclerotic
plaques and elevated levels are found in the circulation of
patients with atherosclerosis (13,57 and our unpublished
data), but its role in the atherogenic processes remains to be
established. 
CD105 is up-regulated in inflammatory conditions such as
RA, psoriasis and tissue repair (29,30,59,60). The results
shown here suggest that the pro-inflammatory factor TNF·
does not contribute to this CD105 up-regulation. It remains
possible that under different experimental conditions, TNF·
has a positive effect on CD105 expression. TNF· plays a
major role in the progression of inflammatory diseases such
as RA, psoriasis as demonstrated by the success of anti-TNF·
therapy in RA (58). However, it is not known what effect anti-
TNF· therapy has on CD105 levels. Quantification of CD105
in diseased tissues and in the circulation of patients pre- and
post-treatment may prove whether it is an appropriate marker
of disease activity.
Systemic sclerosis (SSc) is an autoimmune disease
characterised by the involvement of microvascular damage,
excessive extracellular molecule deposition and fibrosis. In an
unpublished study we have found  up-regulation of CD105 in
the vasculature of skin biopsies taken from patients with SSc.
Further investigation is required to determine the interactions
of TGFßs and CD105 in the pathobiology of this disease.  
The fact that TGFß1 but not TNF· significantly altered
CD105 promoter activity suggests that the TGFß1 regulation
resides, at least in part, at the transcriptional level. The
stimulatory effect of TGFß1 has been previously observed in
mesangial and CD105-transfected U937 cells (15); these
findings are in agreement with the present study. Several
transcriptional elements responsive to TGFß, including the
Smad binding elements found in the CD105 promoter, are
considered to mediate the effect of TGFß1 on CD105
expression (41, 61). By contrast, the CD105 down-regulation
by TNF·, shown in this paper, does not support a
transcriptional involvement. We speculate that under our
experimental conditions, TNF· may induce cleavage of
CD105 by an unknown protease, which requires further
investigation.
The findings in this study, together with the observation
that IFNÁ, a potent anti-angiogenic cytokine, also suppresses
CD105 gene expression in vascular EC (our unpublished
data) lead us to conclude that CD105 expression in the EC is
regulated by the concerted action of a panel of vasoactive
cytokines. As a pro-angiogenic factor, CD105 modulates their
actions on the vasculature. In the context of the
multifunctional property of such cytokines, CD105 appears to
be embedded in a network of signals involved in angiogenesis,
inflammation and immune response. Further studies are
required to elucidate the precise roles of CD105 in these
processes and interactions of CD105 with other intracellular
components.
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